All In Biotech

Drug Trial Radar · NCT03630081

Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

Last checked: Nov 19, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,004 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,004

Planned (sponsor's estimate)

Start

Jan 2024

Primary completion

Jan 2026

Study completion Feb 2026

Sponsor

Lead sponsor
WockhardtIndustry
Sponsor type
Industry
First posted
Aug 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-TAZ vs. meropenem in the treatment of hospitalized adults with cUTI or AP.

Conditions

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis

Interventions

  • WCK 4282 (FEP-TAZ) 4 gDrug

    WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min

  • MeropenemDrug

    1 g IV q8h, infused over 45 min

  • ciprofloxacin 500 mg Optional Oral SwitchDrug

    ciprofloxacin 500 mg PO q12h

  • Infusion of normal salineOther

    Infusion of normal saline over 45 min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with overall success at Day 5Time frame: Day 5
  2. Percentage of subjects with overall success at Test-of-CureTime frame: Test Of Cure Visit (Day 17 ± 2 days)
  3. Percentage of subjects with Treatment-Emergent Adverse Events (TEAE)Time frame: Day 1 to the end of study Late Follow-Up visit (LFU) (26 ± 2 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.